Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2019 1
2020 1
2021 2
2022 1
2023 2
2024 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

6 results

Results by year

Filters applied: . Clear all
Page 1
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Sonneveld P, Dimopoulos MA, Boccadoro M, Quach H, Ho PJ, Beksac M, Hulin C, Antonioli E, Leleu X, Mangiacavalli S, Perrot A, Cavo M, Belotti A, Broijl A, Gay F, Mina R, Nijhof IS, van de Donk NWCJ, Katodritou E, Schjesvold F, Sureda Balari A, Rosiñol L, Delforge M, Roeloffzen W, Silzle T, Vangsted A, Einsele H, Spencer A, Hajek R, Jurczyszyn A, Lonergan S, Ahmadi T, Liu Y, Wang J, Vieyra D, van Brummelen EMJ, Vanquickelberghe V, Sitthi-Amorn A, de Boer CJ, Carson R, Rodriguez-Otero P, Bladé J, Moreau P; PERSEUS Trial Investigators. Sonneveld P, et al. N Engl J Med. 2024 Jan 25;390(4):301-313. doi: 10.1056/NEJMoa2312054. Epub 2023 Dec 12. N Engl J Med. 2024. PMID: 38084760 Clinical Trial.
Safety and tolerability of a 90-minute rapid infusion of Sandoz biosimilar rituximab in B-cell lymphoproliferative disorders in a real-world setting.
Muntañola A, Arguiñano-Pérez JM, Dávila J, de Villambrosia SG, Carpio C, Jiménez-Ubieto A, Salar A; GELTAMO (Grupo español de linfomas y trasplante de médula ósea). Muntañola A, et al. Among authors: arguinano perez jm. Clin Transl Sci. 2023 Feb;16(2):305-312. doi: 10.1111/cts.13450. Epub 2022 Nov 24. Clin Transl Sci. 2023. PMID: 36385738 Free PMC article.
Real-World Characteristics and Outcome of Patients Treated With Single-Agent Ibrutinib for Chronic Lymphocytic Leukemia in Spain (IBRORS-LLC Study).
Abrisqueta P, Loscertales J, Terol MJ, Ramírez Payer Á, Ortiz M, Pérez I, Cuellar-García C, Fernández de la Mata M, Rodríguez A, Lario A, Delgado J, Godoy A, Arguiñano Pérez JM, Berruezo MJ, Oliveira A, Hernández-Rivas JÁ, García Malo MD, Medina Á, García Martin P, Osorio S, Baltasar P, Fernández-Zarzoso M, Marco F, Vidal Manceñido MJ, Smucler Simonovich A, López Rubio M, Jarque I, Suarez A, Fernández Álvarez R, Lancharro Anchel A, Ríos E, Losada Castillo MDC, Pérez Persona E, García Muñoz R, Ramos R, Yáñez L, Bello JL, Loriente C, Acha D, Villanueva M. Abrisqueta P, et al. Among authors: arguinano perez jm. Clin Lymphoma Myeloma Leuk. 2021 Dec;21(12):e985-e999. doi: 10.1016/j.clml.2021.07.022. Epub 2021 Aug 3. Clin Lymphoma Myeloma Leuk. 2021. PMID: 34511320 Free article.
Safety of switching from intravenous to subcutaneous rituximab during first-line treatment of patients with non-Hodgkin lymphoma: the Spanish population of the MabRella study.
García-Muñoz R, Quero C, Pérez-Persona E, Domingo-García A, Pérez-López C, Villaescusa-de-la-Rosa T, Martínez-Castro AM, Arguiñano-Pérez JM, Parra-Cuadrado JF, Panizo C. García-Muñoz R, et al. Among authors: arguinano perez jm. Br J Haematol. 2020 Mar;188(5):661-673. doi: 10.1111/bjh.16227. Epub 2019 Oct 1. Br J Haematol. 2020. PMID: 31573078 Free PMC article. Clinical Trial.
[Mediastinal B-cell lymphoma during pregnancy].
Arteche Eguizabal L, Arguiñano Pérez JM, Becerril Moreno F, González Arnáiz J. Arteche Eguizabal L, et al. Among authors: arguinano perez jm. Farm Hosp. 2008 Mar-Apr;32(2):129-30. doi: 10.1016/s1130-6343(08)72827-7. Farm Hosp. 2008. PMID: 18783715 Free article. Spanish. No abstract available.